[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100606434":3},{"organization":4,"armGroups":7,"interventions":27,"overallOfficials":38,"centralContacts":43,"locations":49,"responsibleParty":66,"collaborators":11,"id":68,"slug":69,"hasResults":70,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":11,"eligibilityCriteria":74,"healthyVolunteers":75,"sex":76,"minAge":77,"maxAge":78,"enrollmentInfo":79,"targetDuration":11,"studyType":82,"phases":83,"briefSummary":85,"conditions":86,"keywords":11,"overallStatus":51,"whyStopped":11,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":97},{"fullName":5,"class":6},"Keymed Biosciences Co.Ltd","INDUSTRY",[8,15,18,21,24],{"label":9,"type":10,"description":11,"interventionNames":12},"CM559 or matched placebo cohort 1","EXPERIMENTAL",null,[13,14],"Drug: Placebo","Biological: CM559",{"label":16,"type":10,"description":11,"interventionNames":17},"CM559 or matched placebo cohort 2",[13,14],{"label":19,"type":10,"description":11,"interventionNames":20},"CM559 or matched placebo cohort 3",[13,14],{"label":22,"type":10,"description":11,"interventionNames":23},"CM559 or matched placebo cohort 4",[13,14],{"label":25,"type":10,"description":11,"interventionNames":26},"CM559 or matched placebo cohort 5",[13,14],[28,33],{"type":29,"name":30,"description":31,"armGroupLabels":32,"otherNames":11},"DRUG","Placebo","Placebo injection administered IV, once.",[9,16,19,22,25],{"type":34,"name":35,"description":36,"armGroupLabels":37,"otherNames":11},"BIOLOGICAL","CM559","CM559 injection administered IV, once.",[9,16,19,22,25],[39],{"name":40,"affiliation":41,"role":42},"Mengchang Yang","Sichuan Provincial People's Hospital","STUDY_CHAIR",[44],{"name":45,"role":46,"phone":47,"phoneExt":11,"email":48},"Qian Jia","CONTACT","028-88610620","qianjia@keymedbio.com",[50],{"facility":41,"status":51,"city":52,"state":53,"zip":11,"country":54,"countryCode":55,"cosmosGeoPoint":56,"geoPoint":61,"contacts":62},"RECRUITING","Chengdu","Sichuan","China","CN",{"type":57,"coordinates":58},"Point",[59,60],104.06667,30.66667,{"lat":60,"lon":59},[63],{"name":40,"role":46,"phone":64,"phoneExt":11,"email":65},"86+ 18140049936","ymc681@126.com",{"type":67,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100606434","phase-1-study-of-cm559-in-healthy-subjects-100606434",false,"NCT07175506","Study of CM559 in Healthy Subjects","A Randomized, Double-blind, Placebo-controlled Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of CM559 in Healthy Subjects With Single Ascending Dose Administration","Inclusion Criteria:\n\n* Subjects age ≥ 18 years \\& ≤60 years.\n* Subjects voluntarily signed the Informed Consent Form and were able to comply with the provisions of this protocol.\n\nExclusion Criteria:\n\n* The average number of cigarettes smoked per day is greater than 5 within 3 months prior to screening.\n* Drinking heavily within 3 months prior to screening, or unable to guarantee not to drink alcohol during the research period, or positive alcohol breath testing.\n* History of drug abuse within 1 year prior to screening, or positive urine drug abuse screening.\n* Blood donation or any other form of blood loss exceeding 400mL, or accepting blood transfusion within 12 weeks prior to screening.\n* Suspected allergy to Aβ-antibody drugs, humanized monoclonal antibody drugs and their excipients, or other biological agents, or have a history of severe allergic reactions to other drugs.\n* Severe trauma or undergo major surgery within 3 months prior to screening,or planned surgery during the research period.",true,"MALE","18 Years","60 Years",{"count":80,"type":81},40,"ESTIMATED","INTERVENTIONAL",[84],"PHASE1","This study is a single center, randomized, double-blind, placebo-controlled, single dose, dose escalation Phase I clinical study aimed at evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of CM559 administered intravenously at different doses in healthy male subjects.",[87],"Healthy Subjects","2025-09-23",{"date":90,"type":91},"2025-09-29","ACTUAL",{"date":93,"type":81},"2025-09",{"date":95,"type":81},"2026-06",{"name":5,"class":6},1]